Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Erfonrilimab - Alphamab

Drug Profile

Erfonrilimab - Alphamab

Alternative Names: Anti-PD-L1 / CTLA-4 bispecific antibody; KN-046

Latest Information Update: 05 Apr 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Alphamab
  • Developer Beijing Cancer Hospital; InxMed; Jiangsu Alphamab Biopharmaceuticals; Peking University; Shanghai Pulmonary Hospital; Suzhou Kintor Pharmaceuticals; Weill Cornell Medical College
  • Class Antineoplastics; Bispecific antibodies; Immunotherapies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; Cytotoxic T-lymphocyte antigen 4 inhibitors; Programmed cell death-1 ligand-1 inhibitors; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Gastric cancer; Thymic epithelial tumour
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Non-small cell lung cancer; Pancreatic cancer
  • Phase II/III Malignant thymoma
  • Phase II Digestive system neoplasms; Gastric cancer; Liver cancer; Oesophageal cancer; Solid tumours
  • Phase I/II Triple negative breast cancer
  • Phase I Lymphoma

Most Recent Events

  • 15 Mar 2024 Peking University Cancer Hospital & Institute completes a phase II trial in Liver cancer (First-line therapy, Combination therapy, Late-stage disease, In adults, In the elderly) in China (IV) (NCT04542837)
  • 12 Mar 2024 Jiangsu Alphamab Biopharmaceuticals terminates a phase II trial for Malignant thymoma (Inoperable/Unresectable, Metastatic disease, Late-stage disease, Second-line therapy) in China due to the adjustment of the sponsor's development strategy(NCT04469725)
  • 12 Dec 2023 Safety and efficacy data from a phase I/II trial in Solid tumours and Lymphoma presented at the 48th European Society for Medical Oncology Congress (ESMO-2023)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top